Related Experiment Video
Updated: Aug 14, 2026
06:10
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
[Therapeutic options in cardiogenic shock]
C Alonso Francia1, I Calvo Cebollero, J A Diarte de Miguel
1Sección de Hemodinámica y Cardiología Intervencionista, Hospital Miguel Servet, Zaragoza.
Revista Espanola De Cardiologia
|September 1, 1995
Summary
Cardiogenic shock, often caused by heart attack, has high mortality. Early revascularization through angioplasty or surgery significantly improves survival rates compared to conventional therapies.
Area of Science:
- Cardiology
- Critical Care Medicine
Background:
- Cardiogenic shock presents a significant clinical challenge with high mortality rates.
- Acute myocardial infarction is the predominant cause of cardiogenic shock.
Purpose of the Study:
- To review the current understanding of cardiogenic shock management.
- To emphasize the importance of early diagnosis and revascularization for improving patient outcomes.
Main Methods:
- Review of existing literature on cardiogenic shock etiology and treatment.
- Analysis of the efficacy of various therapeutic interventions, including pharmacotherapy, circulatory assistance, and revascularization techniques.
Main Results:
- While inotropic drugs and circulatory support offer hemodynamic improvement, they do not significantly reduce mortality.
- Revascularization strategies, particularly angioplasty (70% survival) and bypass surgery (50-60% survival for specific complications), are most effective.
- Conventional therapy for cardiogenic shock carries a 70-90% mortality rate.
Conclusions:
- Aggressive early diagnosis and revascularization, including coronary angiography and angioplasty, are crucial for improving survival in cardiogenic shock.
- Transfer to specialized centers is recommended when advanced diagnostic and therapeutic capabilities are unavailable.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...